【作者】 丁华；

【导师】 王绍丰；

【作者基本信息】 广西医科大学 ， 肿瘤学， 2004， 硕士

【摘要】 目的： 建立外周血单核细胞中谷胱甘肽（GSH）含量的测定方法及正常参考值，并探讨鼻咽癌患者外周血单核细胞中 GSH 含量与放射治疗近期疗效的关系。方法： 采用 Tietze 还原酶法检测 102 例不同性别、不同年龄的健康人外周血单核细胞中 GSH 含量，并观察不同性别、不同年龄组的差别，同时检测 126例鼻咽癌患者外周血单核细胞中 GSH 含量，观察正常人和鼻咽癌患者之间的差异，以及不同临床分期的鼻咽癌患者的 GSH 含量差异，同时观察鼻咽癌患者中 GSH 含量高于健康人群组均数值和低于该数值的两组病人鼻咽肿物的近期疗效情况。结果： 正常人群中外周血单核细胞内 GSH 含量男女分别为：(133.88±72.32)×10-9mmol/L ，(141.51±58.98)×10-9mmol/L，男女值无明显差异（P>0.05），测得各年龄段值：30 岁以下为(132.99±49.16)×10-9mmol/L，30 至 39 岁为(129.00±68.41)×10-9mmol/L，40 至 49 岁为(132.67±47.25)×10-9mmol/L，50 至 59岁为(152.17±73.72)×10-9mmol/L，60 岁以上为(150.84±104.27)×10-9mmol/L。各年龄段 GSH 值无明显差异（P>0.05）。鼻咽癌患者与健康人外周血 GSH 含量分别为(140.03±53.87)×10-9mmol/L 和(138.08±64.92)×10-9mmol/L，两者无明显差异（P>0.05）。Ⅰ、Ⅱ、Ⅲ、Ⅳ期的鼻咽癌患者外周血 GSH 含量分别为(135.66±50.74)×10-9mmol/L，(141.35±69.57)×10-9mmol/L，(149.55± 2<WP=4>79.40)×10-9mmol/L，(136.29±69.31)×10-9mmol/L，含量无明显差异（P>0.05）。鼻咽癌患者中 65 例大于 138×10-9mmol/L（A 组），61 例小于 138×10-9mmol/L（B 组），两组放疗方法相同。放疗结束时两组鼻咽部肿物完全消退率和部分消退率分别为 47.7％、52.3％和 70.5％、29.5％，有明显差异（P<0.05）。结论： Tietze 还原酶法检测外周血单核细胞内的 GSH 含量所测结果可信。GSH 与鼻咽癌的发生、发展无直接关系。鼻咽癌患者外周血单核细胞中 GSH含量高于健康人群组均数值者放疗后肿瘤消退率低，反之则高，该指标可作为预测鼻咽癌放射敏感性及检测内源性 GSH 合成抑制剂作用效果的参考指标。更多还原

【Abstract】 Object: To establish a test method about Glutathione(GSH) content peripheralblood monocytes in healthy people and its reference date. To investigate theclinical significance of GSH content of peripheral blood monocytes in patientswith nasopharyngeal carcinoma.Methods: The GSH contents of periphetsl blood monocytes in 126 cases ofnasopharyngeal patients and 102 cases of healthy persons were determined by ,Tietze methods. And test the GSH content in healthy people s blood in differentsexes and different ages .The difference in contents between nasopharyngealpatients and healthy persons was observed and the recent regression ofnasopharyngeal tumor in nasopharyngeal carcinoma patients whose GSH contentwas higher or lower than the average GSH contents of healthy persons wasanalysed.Results: The GSH contents of peripheral blood monocytes in men and womenwere (133.88±72.32) ×10-9mmol/L and (141.51±58.98)×10-9mmol/L, respectively(P>0.05); the GSH contents in younger than 30 years, 30~39 years, 40~49 years, 50~59years and above 60 years were (132.99±49.16)×10-9mmol/L, (129.00±68.41)×10-9mmol/L,(132.67±47.25)×10-9mmol/L,(152.17±73.72)×10-9mmol/L, (150.84±104.27)×10-9mmol/L respectively (P>0.05). The GSH contents of peripheral 4<WP=6>blood monocytes in nasopharyngeal carcinoma patients and healthy personswere(140.03±53.87)×10-9mmol/L and(138.08±64.92)×10-9mmol/L, respectively.There was no significant difference（P>0.05）. The GSH contents in state Ⅰ, Ⅱ, ,Ⅲ, and Ⅳ nasopharyngeal carcinoma patients blood were (135.66±50.74)×10-9mmol/L，(141.35±69.57)×10-9mmol/L，(149.55±79.40)×10-9mmol/L，(136.29±69.31）×10-9mmol/L, respectively. There was no significant difference（P>0.05）. The two groups accepted the same radiotherapy. After finishedradiotherapy, the complete regression rate and partial regression rate ofnasopharyngeal tumor of the two groups were 47.7％, 52.3％ and 70.5％,29.5％, respectively（P<0.05）.Conclusion: This method is simple and results are reliable. GSH cannot affect theoccurrence and development of Nasopharyngeal carcinoma. The recent regressionrate of nasopharyngeal tumor in the lower GSH content group is higher than thehigher GSH content group. The GSH content of peripheral blood monocytes can beused as an index to forecast radiosensitivity of Nasopharyngeal carcinoma and useGSH synthesis depressant to enhance the radiosensitivity.更多还原